Alimera Sciences, Inc. (ALIM)
| Market Cap | 46.16M |
| Revenue (ttm) | 54.39M |
| Net Income (ttm) | -3.86M |
| Shares Out | 5.07M |
| EPS (ttm) | -0.77 |
| PE Ratio | n/a |
| Forward PE | 35.84 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 25 |
| Last Price | $7.83 |
| Previous Close | $8.00 |
| Change ($) | -0.17 |
| Change (%) | -2.13% |
| Day's Open | 8.00 |
| Day's Range | 7.48 - 8.27 |
| Day's Volume | 37,214 |
| 52-Week Range | 3.12 - 8.68 |
ATLANTA, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescri...
ATLANTA, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the m...
ILUVIEN has been launched for both Diabetic Macular Edema and Non-Infectious Posterior Uveitis Indications ILUVIEN has been launched for both Diabetic Macular Edema and Non-Infectious Posterio...
ATLANTA, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the m...
ATLANTA, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the m...
ATLANTA, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the m...
Alimera Sciences (ALIM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Alimera Sciences, Inc. (ALIM) CEO Rick Eiswirth on Q3 2020 Results - Earnings Call Transcript
Alimera Sciences (ALIM) delivered earnings and revenue surprises of 75.51% and 16.03%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the ...
Rebound Continues from COVID Challenges Rebound Continues from COVID Challenges
Conference Call to be held Thursday, October 29, 2020 at 9:00am Eastern Time Conference Call to be held Thursday, October 29, 2020 at 9:00am Eastern Time
ATLANTA, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for th...
ATLANTA, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescriptio...
ATLANTA, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescriptio...
ATLANTA, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of pres...
ILUVIEN receives pricing and reimbursement approvals for both diabetic macular edema and posterior uveitis indications simultaneously ILUVIEN receives pricing and reimbursement approvals for b...
ATLANTA, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription...
ATLANTA, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription...
Alimera Sciences (ALIM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Alimera Sciences, Inc. (ALIM) CEO Rick Eiswirth on Q2 2020 Results - Earnings Call Transcript
Alimera Sciences (ALIM) delivered earnings and revenue surprises of 76.17% and 336.44%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Alimera Sciences (NASDAQ:ALIM) decreased 1.5% after the company reported Q2 results.
Second Quarter and Recent Company Highlights:
Alimera (ALIM) will provide updates on its corporate developments during the second-quarter 2020 earnings release.
Conference Call to be held Thursday, July 30, 2020 at 9:00 AM Eastern Time Conference Call to be held Thursday, July 30, 2020 at 9:00 AM Eastern Time
A randomized, controlled , multi-center study designed to demonstrate better disease control, reduced retinal damage and a reduction in treatment frequency compared to current standard of care
Alimera Sciences, Inc. (ALIM) CEO Rick Eiswirth on Q1 2020 Results - Earnings Call Transcript
Alimera Sciences (ALIM) delivered earnings and revenue surprises of 44.19% and 3.53%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
ATLANTA, April 13, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of pres...
In a volatile market, it's more important than ever to hone your technical analysis skills. Here are some near-term trading ideas.
ATLANTA, March 31, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM), a leader in the commercialization and development of prescription ophthalmology treatments for the manageme...
ATLANTA, March 25, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or “Company”), a leader in the commercialization and development of prescription ophthalmology tr...
Alimera Sciences, Inc. (ALIM) CEO Rick Eiswirth on Q4 2019 Results - Earnings Call Transcript
Alimera Sciences (ALIM) delivered earnings and revenue surprises of 121.62% and 19.64%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the ...
Company continues to execute on its international expansion strategy
ATLANTA, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for t...
ATLANTA, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for t...
ATLANTA, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or “Company”), a leader in the commercialization and development of prescription ophthalmology tre...
Alimera Sciences, Inc. (ALIM) CEO Richard Eiswirth on Q3 2019 Results - Earnings Call Transcript
Third Quarter and Recent Company Highlights:
Alimera Sciences Announces Equity Purchase Agreement for up to $20 Million with Lincoln Park Capital
ATLANTA, Oct. 25, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for t...
Consolidated net revenue expected to exceed $12.8 million Consolidated net revenue expected to exceed $12.8 million
ATLANTA, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for ...
Second country in Europe where patients now have access to this important new treatment option; marketing to commence immediately Second country in Europe where patients now have access to thi...
Alimera Sciences, Inc. (ALIM) CEO Rick Eiswirth on Q2 2019 Results - Earnings Call Transcript
Alimera Sciences has been struggling lately, but the selling pressure may be coming to an end soon.
Alimera Sciences, Inc. (ALIM) CEO Dan Myers on Q1 2019 Results - Earnings Call Transcript
About ALIM
Alimera Sciences, a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. The company sells its products through direct sales and distributors to physician offices, pharmacies, and hospitals. It has a collaboration ag... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | IPO Date Apr 22, 2010 |
| CEO C. Daniel Myers | Employees 122 |
| Stock Exchange NASDAQ | Ticker Symbol ALIM |
Financial Performance
In 2019, ALIM's revenue was $53.94 million, an increase of 15.76% compared to the previous year's $46.60 million. Losses were -$10.44 million, -36.25% less than in 2018.
Analyst Forecasts
According to 4 analysts, the average rating for ALIM stock is "Strong Buy." The 12-month stock price forecast is 13.50, which is an increase of 72.41% from the latest price.